Work

Cost and availability of novel cell and gene therapies

Year: 2023

Type: article

Abstract: Advanced gene and cellular therapies risk a second "valley of death" due to their high costs and low patient population. As these are life-saving therapies, measures are urgently needed to prevent their withdrawal from the market.

Source: EMBO Reports

DOI: 10.15252/embr.202256661

Authors: Michele De Luca, Giulio Cossu

Institutions: University of Modena and Reggio Emilia, University of Manchester, IRCCS Ospedale San Raffaele

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $6,100

Funder: Medical Research Council

Award: Cell mediated gene therapy for Duchenne muscular dystrophy: trans-correction of resident nuclei to amplify dystrophin expression

OpenAlex ID: W4313406630

FWCI: 6.538

Cites: 14

Cited by: 37

Related to: 10